RBC keeps USD 11.00 target as BioCryst stock closed at USD 7.79 on October 16, 2026

Published on 10/17/2026 at 20:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are scheduled for November 2, 2026. BioCryst stock costs USD 7.79 on October 16, 2026, down 2.87 percent versus Nasdaq's close.

Analyst view and trading position

RBC Capital maintained an USD 11.00 target on October 8, 2026.
BioCryst's next earnings date is November 2, 2026.
BioCryst stock closed at USD 7.79 on October 16, 2026, down 2.87 percent versus the Nasdaq close.
Market capitalization stood at USD 2.0 billion on October 16, 2026.

BCRX, US09058V1035, Illustration mit AI erstellt.

RBC Capital maintained a Hold rating and an USD 11.00 price target for BioCryst Pharmaceuticals on October 8, 2026, putting the target 41.21 percent above the USD 7.79 Nasdaq closing price. According to Markets Insider, RBC analyst Brian Abrahams kept the rating unchanged. BioCryst stock closed at USD 7.79 on October 16, 2026 at 4:00 p.m. ET, down 2.87 percent versus the Nasdaq close.

The next earnings date is November 2

The next scheduled reporting date is November 2, 2026. ToAlpha lists that date for BioCryst Pharmaceuticals. For investors, the calendar date matters because the company has not yet supplied a newer reported period in the material used here.

52-week range and trading volume

BioCryst's 52-week range was USD 6.23 to USD 11.22 on October 16, 2026. The closing price was 30.57 percent below the high and 25.04 percent above the low, placing the stock closer to the lower end of its yearly range. Trading volume reached 4,396,151 shares, 6.80 percent above the 4,116,315-share average on the same date.

Valuation and company profile

BioCryst had a market capitalization of USD 2.0 billion and a trailing P/E ratio of minus 5.19 on October 16, 2026. The company develops oral medicines for rare diseases, with hereditary angioedema among its principal focus areas. Its primary commercial product is Orladeyo, an oral treatment designed to prevent hereditary angioedema attacks.

Comparison with peers

BCRX (Nasdaq, USD): minus 2.87 percent, P/E minus 5.19, market capitalization USD 2.0 billion, as of October 16, 2026.
Halozyme Therapeutics (Nasdaq, USD): plus 0.27 percent, P/E 36.37, market capitalization USD 13.8 billion, as of October 16, 2026.
Novavax (Nasdaq, USD): minus 12.17 percent, P/E minus 7.41, market capitalization USD 1.9 billion, as of October 16, 2026.

The October 16 closing price

BioCryst traded on Nasdaq at USD 7.79 at 4:00 p.m. ET on October 16, 2026. The stock's 52-week high was USD 11.22, while its 52-week low was USD 6.23.